Avantor, Inc.
For the period ended Jun 30, 2025. Filed Aug 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 1, 2025
AVTR$15.91+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Glossaryii
Glossary
| Description | |
| the Company, we, us, our | Avantor, Inc. and its subsidiaries |
|---|---|
| Adjusted EBITDA | our earnings or loss before interest, taxes, depreciation, amortization and certain other adjustments |
| Adjusted Operating Income | our earnings or loss before interest, taxes, amortization and certain other adjustments |
| Advanced Lab Services | Services and products designed to optimize and manage end-to-end laboratory operations for customers across industries such as biopharma, education, industrial, and technology sectors |
| AOCI | accumulated other comprehensive income or loss |
| Applied Solutions | Proprietary formulated solutions for semiconductor manufacturing, proprietary chemicals for healthcare, biopharma, and diagnostic applications as well as chemicals and PPE for industrial applications |
| ASC | Accounting Standards Codification |
| ASU | Accounting Standards Update |
| Bioprocessing | Process ingredients and excipients, single use systems and integrated solutions, and controlled environment consumables used to support the production of biologic drugs and therapies |
| CODM | chief operating decision maker |
| EURIBOR | the basic rate of interest used in lending between banks on the European Union interbank market |
| FASB | the Financial Accounting Standards Board of the United States |
| GAAP | United States generally accepted accounting principles |
| Laboratory Specialty Products | Proprietary chemicals and products for multiple industries, including biopharma, healthcare, industrial, mining, and education, among others |
| long-term | period other than short-term |
| OCI | other comprehensive income or loss |
| RSU | restricted stock units represent awards that will vest annually and awards that contain performance and market conditions |
| SEC | the United States Securities and Exchange Commission |
| SG&A expenses | selling, general and administrative expenses |
| short-term | period less than a year from the reporting date |
| Silicones | Ultra-high purity medical and aerospace grade silicone formulations |
| SOFR | secured overnight financing rate |
| specialty procurement | product sales related to customer procurement services |
| Total Science Solutions | Mission-critical consumables, chemicals, and equipment and instrumentation used by scientists in their labs |
ii
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.